Difference between revisions of "Part:BBa K5099014"
Isabelleguo (Talk | contribs) |
Isabelleguo (Talk | contribs) |
||
Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K5099014 short</partinfo> | <partinfo>BBa_K5099014 short</partinfo> | ||
+ | |||
+ | |||
The Nucle.io project aims to provide rapid, point-of-care diagnostics that undercut current wait times for the return and analysis of laboratory test results such as blood culture (3 days) and PCR (1 day), by performing both diagnostic amplification and result computation in one reaction. This allows clinical decision making to happen on a faster timescale in emergency medical settings where time is of the essence. Sepsis is a disease responsible for 20% of global deaths. Each hour of delayed treatment leads to an 8% increase in mortality. When infection is treated early with accurate antibiotics, downstream complications such as organ failure can be prevented. The Nucle.io diagnostic uses a modular approach to achieve both accuracy and speed, leveraging the CasX protein to perform mRNA-based detection or a strand displacement cascade to perform mRNA amplification. The downstream module (computation) applies the Winner-Take-All neural network (WTA NN), which is a DNA computing architecture using toehold-mediated strand displacement reactions to analyze profiles of nucleic acids developed in Neural network computation with DNA strand displacement cascades (Qian et. al, 2011). | The Nucle.io project aims to provide rapid, point-of-care diagnostics that undercut current wait times for the return and analysis of laboratory test results such as blood culture (3 days) and PCR (1 day), by performing both diagnostic amplification and result computation in one reaction. This allows clinical decision making to happen on a faster timescale in emergency medical settings where time is of the essence. Sepsis is a disease responsible for 20% of global deaths. Each hour of delayed treatment leads to an 8% increase in mortality. When infection is treated early with accurate antibiotics, downstream complications such as organ failure can be prevented. The Nucle.io diagnostic uses a modular approach to achieve both accuracy and speed, leveraging the CasX protein to perform mRNA-based detection or a strand displacement cascade to perform mRNA amplification. The downstream module (computation) applies the Winner-Take-All neural network (WTA NN), which is a DNA computing architecture using toehold-mediated strand displacement reactions to analyze profiles of nucleic acids developed in Neural network computation with DNA strand displacement cascades (Qian et. al, 2011). |
Revision as of 13:37, 12 September 2024
+_tracrRNA_CasX
The Nucle.io project aims to provide rapid, point-of-care diagnostics that undercut current wait times for the return and analysis of laboratory test results such as blood culture (3 days) and PCR (1 day), by performing both diagnostic amplification and result computation in one reaction. This allows clinical decision making to happen on a faster timescale in emergency medical settings where time is of the essence. Sepsis is a disease responsible for 20% of global deaths. Each hour of delayed treatment leads to an 8% increase in mortality. When infection is treated early with accurate antibiotics, downstream complications such as organ failure can be prevented. The Nucle.io diagnostic uses a modular approach to achieve both accuracy and speed, leveraging the CasX protein to perform mRNA-based detection or a strand displacement cascade to perform mRNA amplification. The downstream module (computation) applies the Winner-Take-All neural network (WTA NN), which is a DNA computing architecture using toehold-mediated strand displacement reactions to analyze profiles of nucleic acids developed in Neural network computation with DNA strand displacement cascades (Qian et. al, 2011).
Usage and Biology
CasX is a broad name for a family of Cas proteins later reclassified under Cas12e. McGill iGEM uses DpbCas12e isolated from Deltaproteobacteria due to high in-vitro cleavage activity (variant PlmCas12e displays low activity in-vitro). CasX uses a dual-RNA guide effector composed of a tracrRNA and crRNA. The tracrRNA and crRNA guide complex contains a scaffold stem containing a bubble, an extended stem, and a triplex region.
McGill iGEM hijacks mRNA in solution to force it to form the crRNA of the CasX system. An engineered tracrRNA binds to the crRNA to reconstitute the guide complex of CasX. This allows the enzyme to associate to the RNA and initiate a sequence-specific cleavage event upon a dsDNA target strand with a matching spacer motif that we place in excess in the solution. CasX cuts a sticky end at the 18-22nt region of dsDNA relative to the spacer. This sticky end is repurposed as a toehold in a strand-mediated displacement reaction, which allows the trigger of a fluorescent output upon mRNA detection through hijacking and cleavage of the target DNA.
We test the reengineerability of the tracrRNA through reconstitution of the guide complex, scaffold stem, and bubble of the triplex region with the following guideRNA engineering conditions:
Characterization and Verification
We test the function of the enzyme under two conditions: The enzyme does in fact cleave the target DNA strand, which is verified by a native PAGE gel. The enzyme is able to cleave the DNA strand which triggers the cascade that causes fluorescent readouts.
We annealed the dsDNA templates for the tracrRNAs and crRNAs in 1:1 stoichiometric ratio in 1xTE/10x Mg2++ (final concentration 12.5mM). The dsDNA templates carried the T7 promoter for RNA transcription. dsDNA templates and target strands verified by DNA-PAGE. The RNAs were transcribed overnight and then purified, then verified by denaturing UREA-PAGE. See below:
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]